A three-part analysis: prescription rates, stigma adjustment, and what the underlying prevalence actually looks like.
U.S. women are prescribed psychiatric medications at roughly twice the rate of men. The headline number — a 2.3x prescription gap for SSRI/SNRI antidepressants — is real, but it does not reflect a 2.3x difference in actual mental illness.
When the data is normalized for two well-documented factors — male under-use of mental health services driven by stigma, and male under-diagnosis driven by atypical symptom presentation — the gap collapses from 2.3x to roughly 1.2x. Broader-symptom prevalence research suggests the underlying rate of psychiatric distress is essentially equal between sexes.
The cleanest single data point comes from Milani et al. (2021), tracking insured U.S. adults from 2018 to 2021. SSRI/SNRI prescribing in women rose from 12.8% to 15.2%. In men, it rose from 5.6% to 6.7%. That is a 2.27x ratio — women are prescribed antidepressants at more than double the male rate.
Aggregating across drug classes from the source PDFs and corroborating CDC NHANES data:
| Drug Class | Women | Men | Ratio (F:M) |
|---|---|---|---|
| Any psychiatric medication (adults) | ~21% | ~10% | 2.10x |
| SSRI / SNRI antidepressants (adults, 2021) | 15.2% | 6.7% | 2.27x |
| Benzodiazepines & Z-hypnotics | ~15% | ~9% | 1.67x |
| Antipsychotics (adults) | ~1.6% | ~1.2% | 1.33x |
| Antidepressants (adolescents 12–19) | 4.5% | 2.0% | 2.25x |
| ADHD stimulants (adolescents 12–19) | 2.2% | 4.2% | 0.52x (M leads) |
Women lead in every class except ADHD medication in youth. The two largest classes by prescription volume — antidepressants and anxiolytics — show a roughly 2x female-to-male ratio. This is the gap that drives the popular framing that "women have more mental illness." The remaining sections test whether that framing is correct.
The stigma research is unambiguous: men have higher self-stigma, more negative attitudes toward treatment, and lower professional help-seeking. The Üzümçeker (2025) meta-analysis confirms traditional masculinity is among the strongest predictors of male non-engagement with mental health services. Two adjustments are needed.
SAMHSA NSDUH consistently shows that among adults with diagnosed Any Mental Illness, women access mental health services at roughly 1.4x the male rate — about 51% of women with AMI receive services versus 37% of men in recent years.
If men sought care at the female rate, men's SSRI/SNRI prescription rate would rise from 6.7% to approximately 9.4%. The female-to-male ratio drops from 2.27x to 1.62x.
Even when men reach a clinician, depression presents atypically. Standard DSM criteria emphasize sadness, tearfulness, hopelessness, and withdrawal. Men more often present with irritability, anger, risk-taking behavior, and alcohol or substance use. Multiple studies estimate men are under-diagnosed for depression by 25–35% relative to actual symptom load when only standard criteria are applied.
Apply a 1.3x correction to the help-seeking-adjusted male rate of 9.4%, and men's effective SSRI/SNRI prescription rate would be roughly 12.2%. Compared to women at 15.2%, the ratio drops to about 1.25x.
| Adjustment Stage | Women | Men | Ratio (F:M) |
|---|---|---|---|
| Raw SSRI / SNRI prescription rate | 15.2% | 6.7% | 2.27x |
| After adjusting for help-seeking gap | 15.2% | 9.4% | 1.62x |
| After adjusting for diagnostic under-detection | 15.2% | 12.2% | 1.25x |
Roughly half of the apparent prescription gap is driven by men not entering the system, and roughly another quarter is driven by men not being correctly identified once they do. Only the final ~1.25x residual could plausibly reflect a true difference in underlying disorder prevalence — and Section C tests whether even that residual is real.
Standard U.S. surveillance data (NSDUH 2021, NIMH) reports the following:
| Disorder | Women | Men | Ratio |
|---|---|---|---|
| Any mental illness, past year | 27.2% | 18.1% | 1.50x |
| Major depressive episode | 10.3% | 6.2% | 1.66x |
| Any anxiety disorder, lifetime | ~33% | ~22% | 1.50x |
| Substance use disorder | ~13% | ~22% | 0.59x (M leads) |
| ADHD (adult) | ~4.2% | ~5.4% | 0.78x (M leads) |
| Suicide attempts | Higher | Lower | F leads ~1.6x |
| Suicide deaths | Lower | Higher | M leads ~3.9x |
On a surface reading, women have ~1.5x the rate of mental illness. That reading is contested by the strongest piece of evidence in this analysis.
Published in JAMA Psychiatry, Martin and colleagues reanalyzed the National Comorbidity Survey Replication using a "male-typical depression" scale alongside standard DSM symptoms. The male-typical scale included anger attacks, aggression, risk-taking, substance abuse, and hyperactivity — symptoms that depression research has long acknowledged but that standard diagnostic instruments do not score.
Men die by suicide at nearly 4x the female rate. That is not consistent with men having half the underlying psychological distress. It is consistent with men having comparable distress, lower help-seeking, atypical presentation that escapes detection, and more lethal coping mechanisms.
Three nested gaps, each one smaller than the last:
| Layer | F:M Ratio |
|---|---|
| Raw prescription gap (SSRI / SNRI) | ~2.3x |
| After normalizing for stigma and help-seeking | ~1.6x |
| After normalizing for male-pattern under-diagnosis | ~1.2x |
| Underlying prevalence (broad-symptom measurement) | ~1.0–1.1x |
The widely-quoted statistic — "women are diagnosed and medicated at twice the rate of men" — is true as a prescription number. It is not true as a statement about underlying mental illness. The best evidence indicates men and women carry roughly comparable rates of psychiatric distress. The 2x prescription gap is approximately half behavioral (men do not seek help due to masculinity-coded stigma) and half diagnostic (men present with externalizing symptoms that fall outside standard depression criteria).
Closing the suicide gap and improving male mental health outcomes will not be achieved by prescribing more SSRIs to women. It requires three structural moves: stigma reduction targeted at masculinity norms, screening tools that score male-pattern symptoms (anger, risk-taking, substance use) as depression indicators, and earlier intervention pathways that men will actually use.